Cazanat 40mg Tablet (Axitinib) is a potent VEGFR-TKI approved for treatment-naive and previously treated metastatic renal cell carcinoma. Composition: Each tablet contains 40mg Axitinib. Indications: Metastatic RCC as first-line or post-sunitinib/sorafenib therapy; thyroid cancer in select cases. Contraindications: Severe hypertension, active bleeding, recent thrombosis, severe hepatic impairment. Relative caution with cardiac disease, brain metastases. Drug Interactions: CYP3A4 modulation, warfarin requiring INR monitoring, strong inhibitors increasing levels. Dosage: 5mg twice daily, titratable to 7mg BD based on tolerability and BP control. Storage: 15-30°C. Side Effects: Hypertension (40-60%), diarrhea, fatigue, nausea, hand-foot syndrome. Serious: cardiac events, GI perforation, hepatotoxicity, arterial thromboembolism. Precautions: Twice-weekly BP monitoring first month then monthly; monthly LFTs; baseline/periodic ECG; renal function monitoring. Pregnancy: Category D contraindicated. Substitutes:

Sorafenib, Sunitinib, Pazopanib for RCC. FAQs: Response 4-8 weeks;

hypertension management critical; cost varies. Timeline: Week 2 tolerability, Week 4 clinical, Week 8 imaging, Month 3 response. Consultation: Hypertension management, cardiac monitoring, surveillance. Tests: Baseline/monthly BP, LFTs, renal function; baseline ECG; monthly imaging.